Want to see RMD full AI Analyst Report?

Resmed (RMD) Stock Forecast & Price Target

1,208 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RMD Analyst Ratings

Moderate Buy

5 Buy

8 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Resmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RMD Stock 12 Month Forecast

Average Price Target

$244.70

▲(3.79% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $244.70 with a high forecast of $320.00 and a low forecast of $213.00. The average price target represents a 3.79% change from the last price of $235.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"184":"$184","321":"$321","218.25":"$218.3","252.5":"$252.5","286.75":"$286.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":320,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$320.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":244.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$244.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":213,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$213.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[184,218.25,252.5,286.75,321],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,221.15,228.75384615384615,236.3576923076923,243.96153846153845,251.56538461538463,259.16923076923075,266.7730769230769,274.37692307692305,281.9807692307692,289.5846153846154,297.1884615384615,304.7923076923077,312.3961538461539,{"y":320,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,221.15,222.96153846153845,224.77307692307693,226.58461538461538,228.39615384615385,230.2076923076923,232.01923076923077,233.83076923076922,235.6423076923077,237.45384615384614,239.26538461538462,241.07692307692307,242.8884615384615,{"y":244.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,221.15,220.52307692307693,219.89615384615385,219.26923076923077,218.6423076923077,218.01538461538462,217.38846153846154,216.76153846153846,216.1346153846154,215.5076923076923,214.88076923076923,214.25384615384615,213.62692307692308,{"y":213,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":268.014,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.295,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.364,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.915,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.672,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.892,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.553,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.827,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.906,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.524,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.376,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231.36,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.15,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$320.00

Average Price Target$244.70

Lowest Price Target$213.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anthony Petrone

Mizuho Securities

$235→$240

Buy

1.80%

Upside

Assigned

10/13/26

ResMed price target raised to $240 from $235 at MizuhoResMed price target raised to $240 from $235 at Mizuho

Lyanne Harrison

Bank of America Securities

$320

Buy

35.73%

Upside

Reiterated

10/13/26

Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD) and Bristol-Myers Squibb (NYSE: BMY)

Jonathan Block

Stifel Nicolaus

$235

Hold

-0.32%

Downside

Reiterated

10/02/26

Stifel Nicolaus Sticks to Its Hold Rating for Resmed (RMD)

Craig Wong-Pan

RBC Capital

$244→$262

Buy

11.13%

Upside

Upgraded

09/15/26

ResMed upgraded to Outperform from Sector Perform at RBC CapitalResMed upgraded to Outperform from Sector Perform at RBC Capital

Laura Sutcliffe

Citi

$235→$240

Hold

1.80%

Upside

Reiterated

09/10/26

ResMed price target raised to $240 from $235 at CitiResMed price target raised to $240 from $235 at Citi

Brett Fishbin

KeyBanc

$255→$267

Buy

13.25%

Upside

Reiterated

08/31/26

Analysts Are Bullish on Top Healthcare Stocks: Resmed (RMD), Cytokinetics (CYTK)

Jackson Philips

Rothschild & Co Redburn

Not Ranked

Rothschild & Co Redburn

$230

Hold

-2.44%

Downside

Initiated

08/19/26

ResMed initiated with a Neutral at Rothschild & Co RedburnResMed initiated with a Neutral at Rothschild & Co Redburn

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

―

Hold

―

Assigned

08/07/26

Oppenheimer Issues a Hold Rating on Resmed (RMD)

Adam Maeder

Piper Sandler

$225

Hold

-4.56%

Downside

Reiterated

08/07/26

Piper Sandler Sticks to Its Hold Rating for Resmed (RMD)

Michael Matson

Needham

―

Hold

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and High Tide (NASDAQ: HITI)

David Rescott

Robert W. Baird

$217→$213

Hold

-9.65%

Downside

Reiterated

08/07/26

ResMed price target lowered to $213 from $217 at BairdResMed price target lowered to $213 from $217 at Baird

Nathan Treybeck

Wells Fargo

$225→$215

Hold

-8.81%

Downside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)

David Bailey

Morgan Stanley

$230

Hold

-2.44%

Downside

Reiterated

07/13/26

Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged

Matthew Taylor

Jefferies

$225

Hold

-4.56%

Downside

Reiterated

07/10/26

Jefferies Issues a Hold Rating on Resmed (RMD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anthony Petrone

Mizuho Securities

$235→$240

Buy

1.80%

Upside

Assigned

10/13/26

ResMed price target raised to $240 from $235 at MizuhoResMed price target raised to $240 from $235 at Mizuho

Lyanne Harrison

Bank of America Securities

$320

Buy

35.73%

Upside

Reiterated

10/13/26

Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD) and Bristol-Myers Squibb (NYSE: BMY)

Jonathan Block

Stifel Nicolaus

$235

Hold

-0.32%

Downside

Reiterated

10/02/26

Stifel Nicolaus Sticks to Its Hold Rating for Resmed (RMD)

Craig Wong-Pan

RBC Capital

$244→$262

Buy

11.13%

Upside

Upgraded

09/15/26

ResMed upgraded to Outperform from Sector Perform at RBC CapitalResMed upgraded to Outperform from Sector Perform at RBC Capital

Laura Sutcliffe

Citi

$235→$240

Hold

1.80%

Upside

Reiterated

09/10/26

ResMed price target raised to $240 from $235 at CitiResMed price target raised to $240 from $235 at Citi

Brett Fishbin

KeyBanc

$255→$267

Buy

13.25%

Upside

Reiterated

08/31/26

Analysts Are Bullish on Top Healthcare Stocks: Resmed (RMD), Cytokinetics (CYTK)

Jackson Philips

Rothschild & Co Redburn

Not Ranked

Rothschild & Co Redburn

$230

Hold

-2.44%

Downside

Initiated

08/19/26

ResMed initiated with a Neutral at Rothschild & Co RedburnResMed initiated with a Neutral at Rothschild & Co Redburn

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

―

Hold

―

Assigned

08/07/26

Oppenheimer Issues a Hold Rating on Resmed (RMD)

Adam Maeder

Piper Sandler

$225

Hold

-4.56%

Downside

Reiterated

08/07/26

Piper Sandler Sticks to Its Hold Rating for Resmed (RMD)

Michael Matson

Needham

―

Hold

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and High Tide (NASDAQ: HITI)

David Rescott

Robert W. Baird

$217→$213

Hold

-9.65%

Downside

Reiterated

08/07/26

ResMed price target lowered to $213 from $217 at BairdResMed price target lowered to $213 from $217 at Baird

Nathan Treybeck

Wells Fargo

$225→$215

Hold

-8.81%

Downside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)

David Bailey

Morgan Stanley

$230

Hold

-2.44%

Downside

Reiterated

07/13/26

Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged

Matthew Taylor

Jefferies

$225

Hold

-4.56%

Downside

Reiterated

07/10/26

Jefferies Issues a Hold Rating on Resmed (RMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

SIBNSI-Bone

IMUXImmunic

MDWDMediwound

HROWHarrow Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

3 Months

Anthony PetroneMizuho Securities

Success Rate

15/25 ratings generated profit

Average Return

+2.87%

Copying Anthony Petrone's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.87% per trade.

1 Year

Brett FishbinKeyBanc

Success Rate

11/15 ratings generated profit

Average Return

+6.01%

Copying Brett Fishbin's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +6.01% per trade.

2 Years

Lyanne HarrisonBank of America Securities

Success Rate

19/29 ratings generated profit

Average Return

+14.80%

Copying Lyanne Harrison's trades and holding each position for 2 Years would result in 65.52% of your transactions generating a profit, with an average return of +14.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RMD Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RMD has received 7 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. RMD average Analyst price target in the past 3 months is 244.70.

Each month's total comprises the sum of three months' worth of ratings.

RMD Financial Forecast

RMD Earnings Forecast

Next quarter’s earnings estimate for RMD is $2.69 with a range of $2.61 to $2.78. The previous quarter’s EPS was $2.95. RMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RMD has Performed in-line its overall industry.

RMD Sales Forecast

Next quarter’s sales forecast for RMD is $1.39B with a range of $1.36B to $1.42B. The previous quarter’s sales results were $1.46B. RMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RMD has Performed in-line its overall industry.

RMD Stock Forecast FAQ

What is RMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Resmed’s 12-month average price target is 244.70.

What is RMD’s upside potential, based on the analysts’ average price target?

Resmed has 3.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RMD a Buy, Sell or Hold?

Resmed has a consensus rating of Moderate Buy which is based on 5 buy ratings, 8 hold ratings and 0 sell ratings.

What is Resmed’s price target?

The average price target for Resmed is 244.70. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $320.00 ,the lowest forecast is $213.00. The average price target represents 3.79% Increase from the current price of $235.76.

What do analysts say about Resmed?

Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of RMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Resmed (RMD) Stock Forecast & Price Target

RMD Analyst Ratings

RMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Resmed

RMD Analyst Recommendation Trends

RMD Financial Forecast

RMD Earnings Forecast

RMD Sales Forecast

RMD Stock Forecast FAQ

Detailed List of Analyst Forecasts